Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10195234 | 0.85 | MAP2K1 (0.67) | MAP2K1MAP2K2 | |
| SCHEMBL10291313 | 0.84 | MAP2K1 (0.80) | MAP2K1MAP2K2 | |
| SCHEMBL392485 | 0.84 | MAP2K1 (0.81) | MAP2K1MAP2K2 | |
| SCHEMBL388535 | 0.84 | MAP2K1 (0.81) | MAP2K1MAP2K2 | |
| SCHEMBL17227674 | 0.83 | MAP2K1 (0.84) | MAP2K1MAP2K2 | |
| SCHEMBL391162 | 0.81 | MAP2K1 (0.81) | MAP2K1MAP2K2 | |
| SCHEMBL391336 | 0.81 | MAP2K1 (1.00) | MAP2K1MAP2K2 | |
| SCHEMBL392797 | 0.80 | MAP2K1 (1.00) | MAP2K1MAP2K2 | |
| SCHEMBL388478 | 0.80 | MAP2K1 (0.81) | MAP2K1MAP2K2 | |
| SCHEMBL391331 | 0.80 | MAP2K1 (0.73) | MAP2K1MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2930170-B1 | PYRIDONE COMPOUND FOR USE IN THE TREATMENT OF DERMATOLOGICAL DISORDERS | KYOWA KIRIN CO LTD (JP) | 2020-02-05 | — | — | EP | disclosed |
| US-9643952-B2 | Pyridone compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-05-09 | — | — | US | disclosed |
| US-9643952-B2 | Pyridone compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-05-09 | — | — | US | disclosed |
| WO-2015182734-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | 協和発酵キリン株式会社 | 2015-12-03 | — | — | WO | disclosed |
| US-20150315172-A1 | PYRIDONE COMPOUND | KYOWA KIRIN CO., LTD. (JP) | 2015-11-05 | — | — | US | disclosed |
| US-20150315172-A1 | PYRIDONE COMPOUND | KYOWA KIRIN CO., LTD. (JP) | 2015-11-05 | — | — | US | disclosed |
| EP-2930170-A1 | PYRIDONE COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2015-10-14 | — | — | EP | disclosed |
| WO-2014088085-A1 | PYRIDONE COMPOUND | 協和発酵キリン株式会社 (JP) | 2014-06-12 | — | — | WO | disclosed |
| US-8431574-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20130018075-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA, INC. | 2013-01-17 | — | — | US | disclosed |
| EP-2251327-A2 | Heterocyclic inhibitors of MEK and methods of use thereof | Array Biopharma, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| US-7732616-B2 | Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-20100063053-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2010-03-11 | — | — | US | disclosed |
| US-7598383-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090215834-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090209542-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090143389-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090143579-A1 | Heterocyclic Inhibitors of MEK and Methods of Use Thereof | ARRAY BIOPHARMA INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-7517994-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20070112038-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112038-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, MAPK9 | MAP2K1 73/4885MAP2K2 63/4885 |
| US-20090143389-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | NRAS, BRAF, MAPK9 | MAP2K1 91/4885MAP2K2 82/4885 |
| US-20100063053-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | NRAS, BRAF, MAPK9 | MAP2K1 73/4885MAP2K2 63/4885 |
| US-20150315172-A1 | PYRIDONE COMPOUND | HRH4, HRH3, HRH1 | MAP2K1 2893/4885MAP2K2 3081/4885 |
| US-20090215834-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | NRAS, BRAF, MAPK9 | MAP2K1 100/4885MAP2K2 78/4885 |
| US-20130018075-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | NRAS, BRAF, RAF1 | MAP2K1 45/4885MAP2K2 34/4885 |
| US-20090143579-A1 | Heterocyclic Inhibitors of MEK and Methods of Use Thereof | NRAS, BRAF, MAPK9 | MAP2K1 85/4885MAP2K2 69/4885 |
| US-20090209542-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | NRAS, BRAF, MAPK9 | MAP2K1 98/4885MAP2K2 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.